These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 26384674)

  • 1. Sclerostin-antibody treatment of glucocorticoid-induced osteoporosis maintained bone mass and strength.
    Yao W; Dai W; Jiang L; Lay EY; Zhong Z; Ritchie RO; Li X; Ke H; Lane NE
    Osteoporos Int; 2016 Jan; 27(1):283-294. PubMed ID: 26384674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sclerostin antibody and interval treadmill training effects in a rodent model of glucocorticoid-induced osteopenia.
    Achiou Z; Toumi H; Touvier J; Boudenot A; Uzbekov R; Ominsky MS; Pallu S; Lespessailles E
    Bone; 2015 Dec; 81():691-701. PubMed ID: 26409255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progressive increases in bone mass and bone strength in an ovariectomized rat model of osteoporosis after 26 weeks of treatment with a sclerostin antibody.
    Li X; Niu QT; Warmington KS; Asuncion FJ; Dwyer D; Grisanti M; Han CY; Stolina M; Eschenberg MJ; Kostenuik PJ; Simonet WS; Ominsky MS; Ke HZ
    Endocrinology; 2014 Dec; 155(12):4785-97. PubMed ID: 25259718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sclerostin Antibody Reverses Bone Loss by Increasing Bone Formation and Decreasing Bone Resorption in a Rat Model of Male Osteoporosis.
    Li X; Ominsky MS; Villasenor KS; Niu QT; Asuncion FJ; Xia X; Grisanti M; Wronski TJ; Simonet WS; Ke HZ
    Endocrinology; 2018 Jan; 159(1):260-271. PubMed ID: 29069393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of sclerostin antibody plus parathyroid hormone (1-34) on bone formation in ovariectomized rats.
    Wu J; Cai XH; Qin XX; Liu YX
    Z Gerontol Geriatr; 2018 Jul; 51(5):550-556. PubMed ID: 28364259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sclerostin antibody treatment enhances bone strength but does not prevent growth retardation in young mice treated with dexamethasone.
    Marenzana M; Greenslade K; Eddleston A; Okoye R; Marshall D; Moore A; Robinson MK
    Arthritis Rheum; 2011 Aug; 63(8):2385-95. PubMed ID: 21484764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adult Brtl/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength.
    Sinder BP; White LE; Salemi JD; Ominsky MS; Caird MS; Marini JC; Kozloff KM
    Osteoporos Int; 2014 Aug; 25(8):2097-107. PubMed ID: 24803333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapidly growing Brtl/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment.
    Sinder BP; Salemi JD; Ominsky MS; Caird MS; Marini JC; Kozloff KM
    Bone; 2015 Feb; 71():115-23. PubMed ID: 25445450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sclerostin inhibition prevents spinal cord injury-induced cancellous bone loss.
    Beggs LA; Ye F; Ghosh P; Beck DT; Conover CF; Balaez A; Miller JR; Phillips EG; Zheng N; Williams AA; Aguirre JI; Wronski TJ; Bose PK; Borst SE; Yarrow JF
    J Bone Miner Res; 2015 Apr; 30(4):681-9. PubMed ID: 25359699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of sclerostin antibodies in animal models of osteoporosis.
    Ominsky MS; Boyce RW; Li X; Ke HZ
    Bone; 2017 Mar; 96():63-75. PubMed ID: 27789417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sclerostin Blockade and Zoledronic Acid Improve Bone Mass and Strength in Male Mice With Exogenous Hyperthyroidism.
    Tsourdi E; Lademann F; Ominsky MS; Rijntjes E; Köhrle J; Misof BM; Roschger P; Klaushofer K; Hofbauer LC; Rauner M
    Endocrinology; 2017 Nov; 158(11):3765-3777. PubMed ID: 28973221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel flavonoid C-glucoside from Ulmus wallichiana preserves bone mineral density, microarchitecture and biomechanical properties in the presence of glucocorticoid by promoting osteoblast survival: a comparative study with human parathyroid hormone.
    Khan MP; Mishra JS; Sharan K; Yadav M; Singh AK; Srivastava A; Kumar S; Bhaduaria S; Maurya R; Sanyal S; Chattopadhyay N
    Phytomedicine; 2013 Nov; 20(14):1256-66. PubMed ID: 23928508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats.
    Stolina M; Dwyer D; Niu QT; Villasenor KS; Kurimoto P; Grisanti M; Han CY; Liu M; Li X; Ominsky MS; Ke HZ; Kostenuik PJ
    Bone; 2014 Oct; 67():305-13. PubMed ID: 25093263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats.
    Li X; Ominsky MS; Warmington KS; Niu QT; Asuncion FJ; Barrero M; Dwyer D; Grisanti M; Stolina M; Kostenuik PJ; Simonet WS; Paszty C; Ke HZ
    Endocrinology; 2011 Sep; 152(9):3312-22. PubMed ID: 21733832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.
    Li X; Ominsky MS; Warmington KS; Morony S; Gong J; Cao J; Gao Y; Shalhoub V; Tipton B; Haldankar R; Chen Q; Winters A; Boone T; Geng Z; Niu QT; Ke HZ; Kostenuik PJ; Simonet WS; Lacey DL; Paszty C
    J Bone Miner Res; 2009 Apr; 24(4):578-88. PubMed ID: 19049336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sclerostin-Antibody Treatment Decreases Fracture Rates in Axial Skeleton and Improves the Skeletal Phenotype in Growing oim/oim Mice.
    Cardinal M; Dessain A; Roels T; Lafont S; Ominsky MS; Devogelaer JP; Chappard D; Mabilleau G; Ammann P; Nyssen-Behets C; Manicourt DH
    Calcif Tissue Int; 2020 May; 106(5):494-508. PubMed ID: 32025752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does Sclerostin Depletion Stimulate Fracture Healing in a Mouse Model?
    Alzahrani MM; Rauch F; Hamdy RC
    Clin Orthop Relat Res; 2016 May; 474(5):1294-302. PubMed ID: 26608966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of alfacalcidol on cancellous and cortical bone mass in rats treated with glucocorticoid: a bone histomorphometry study.
    Iwamoto J; Seki A; Takeda T; Yamada H; Sato Y; Yeh JK
    J Nutr Sci Vitaminol (Tokyo); 2007 Jun; 53(3):191-7. PubMed ID: 17874822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential temporal effects of sclerostin antibody and parathyroid hormone on cancellous and cortical bone and quantitative differences in effects on the osteoblast lineage in young intact rats.
    Ominsky MS; Brown DL; Van G; Cordover D; Pacheco E; Frazier E; Cherepow L; Higgins-Garn M; Aguirre JI; Wronski TJ; Stolina M; Zhou L; Pyrah I; Boyce RW
    Bone; 2015 Dec; 81():380-391. PubMed ID: 26261096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones.
    Ominsky MS; Li C; Li X; Tan HL; Lee E; Barrero M; Asuncion FJ; Dwyer D; Han CY; Vlasseros F; Samadfam R; Jolette J; Smith SY; Stolina M; Lacey DL; Simonet WS; Paszty C; Li G; Ke HZ
    J Bone Miner Res; 2011 May; 26(5):1012-21. PubMed ID: 21542004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.